Podcasts about Chemotherapy

Lexi Silver is 15 years old. She lost both of her parents before she turned 11. That should tell you enough—but it doesn't. Because Lexi isn't here for your pity. She's not a sob story. She's not a trauma statistic. She's a writer, an advocate, and one of the most emotionally intelligent people you'll ever hear speak into a microphone.In this episode, Lexi breaks down what grief actually feels like when you're a kid and the adults around you just don't get it. She talks about losing her mom on Christmas morning, her dad nine months later, how the system let her down, and how Instagram trolls tell her she's faking it for attention. She also explains why she writes, what Experience Camps gave her, how she channels anger into poems, and what to say—and not say—to someone grieving.Her life isn't a Netflix drama. But it should be.And by the way, she's not “so strong.” She's just human. You'll never forget this conversation.RELATED LINKS• Lexi on Instagram: @meet.my.grief• Buy her book: The Girl Behind Grief's Shadow• Experience CampsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Young people on the Right increasingly realize that the past 10 years were a waste of time and failed to stop the inexorable march into globalist techno-fascism that has destroyed our economic and social future. The problem is that this will just lead to political chemotherapy, where the young Right increasingly dabbles in dark ideas as a reactionary force that is not constructive to combatting the challenges of our time. Also, I show how MAGA Inc. has already quietly moved on to JD Vance as its leader, but the members won't publicly break with Trump on Epstein beyond a few days of complaining. Finally, every day we see more stories of how AI is oversold to the public, yet there are no effective leaders on the Right combatting it. Learn more about your ad choices. Visit megaphone.fm/adchoices

In one of the most emotionally raw and inspirational interviews yet on Six Weeks to Fitness, I had the honor of sitting down with DK Kang—mindset-driven author, martial artist, and wellness advocate—for Episode 237. But DK is not just a coach, a black belt, or a plant-based wellness warrior. He is a survivor of life's most grueling tests, and what he shared with us was nothing short of transformative. DK's story is steeped in pain, perseverance, and deep faith. He and his wife endured a decade-long battle with infertility—years filled with dashed hopes, invasive surgeries, and an eventual hysterectomy that ended their dream of becoming parents. But the struggle didn't stop there. As DK put it, “In this world you will have trouble,” and trouble came knocking again when his wife was diagnosed with a severe abdominal abscess during the height of the COVID-19 pandemic. DK had to drop her off at the emergency room without knowing if she'd make it through surgery. The complications were extreme—spreading from her uterus to her abdomen, intestines, and even her ureter. Then came another blow: a breast cancer diagnosis in late 2023. As DK was reading The Breast Cancer Husband in an effort to better support his wife, he decided to request a flexible work schedule to help her through treatment. The result? He was laid off just a week later. With both of them now jobless and battling a life-threatening illness, DK did what most wouldn't—he laughed. “I went home that night and just started laughing,” he recalled. “Okay, God. Why not us?” It was this mindset—a deep spiritual resilience, bolstered by his martial arts discipline and anchored in love—that carried DK and his wife through. With no income and no safety net, they threw themselves into learning. They studied plant-based nutrition, leaned into spiritual support, and adopted holistic healing practices. “We went completely plant-based,” DK explained. “We grew our own broccoli sprouts because they contain ten times the cancer-fighting compounds of regular broccoli. We started walking daily. We fought forward together—body, mind, and spirit.” Today, DK's wife is in remission. But their journey isn't over. Chemotherapy has left her with cataracts and early-stage osteopenia. Yet DK's energy remains grounded and strong. “We take it day by day. We focus on feeding the mind, fueling the body, and healing from the inside out.” Beyond his personal story, DK's perspective on mindset is both practical and empowering. His book Mindset Metamorphosis was born in the chaos of his wife's treatment and his own unemployment. It challenges readers to reframe limiting thoughts. “Instead of saying, ‘I could never run a 50K,' ask ‘How can I prepare for it?' Start with small wins—put on your shoes. That's a win. Walk to the door. Another win. Train your brain to believe in forward motion.” We also discussed his cultural roots and the wellness practices he inherited from growing up Korean in small-town Missouri. From a young age, DK turned hardship into growth. At just 12, he gave up soda and began training obsessively—not to look good, but to feel good. “The more I trained, the more I could eat,” he laughed, referencing his family's restaurant. And thanks to his mother, who made homemade kimchi, DK developed a lifelong love for gut-healthy, fermented foods. That passion became another book: The Kimchi Connection Cookbook, a resource to help people integrate fermented foods into modern meals. “Your gut is like a garden. If you feed it junk, it produces junk. But if you feed it life, it will produce vitality.” DK now makes his own kimchi in glass jars and encourages people to combine it with tacos, salads, or even spaghetti. “Kimchi isn't just a Korean side dish—it's a healing superfood.” What truly stood out in our conversation was DK's unwavering commitment to faith, family, and service. When I asked him how others can begin to reclaim their life from burnout or hardship, his answer was simple: “Get up. Learn something new. Take action. Find a community. And grow.” He emphasized the importance of self-care, nature, accountability partners, and limiting negativity from social media. “Even a walk in the woods or five minutes of breathing deeply outside can recalibrate your spirit.” DK's journey reminds us that our lowest moments are not the end of our story. They're often the start of something greater. He and his wife turned illness into education, unemployment into purpose, and pain into power. And their story is still being written. If you or someone you know is struggling—with illness, grief, burnout, or simply the weight of life—this is the episode you need to hear. Listen to Episode 237 of Six Weeks to Fitness to learn how to transform struggle into strength with mindset, movement, and mission.

"We really are having the best of times during the worst of times." I'm fresh off my third round of chemotherapy (round two was rough!), and am back on the couch recording with friends. This time for chemo, I was joined by my best friend (and former Dance Spirit colleague!) Michael Anne Bailey, and this is our recap from the day at the infusion center and the few days we spent together. We share our friendship origin story, gush about the things we love most about each other, and talk a lot about eyebrows. SPONSOR:  New Balance: Click here to get your hands on the just-released Rebel v5! Follow Ali: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!

“A great thing about having cancer is people are so nice to you!” This is my attempt to catch you up on what life has looked like since Chemo Round 2. Buckle up! SPONSORS:  UCAN: Click here to get a FREE UCAN sample pack (you'll just pay the cost of shipping), and use code ALI for 20% off your entire UCAN order. Vuori: Click here for 20% off your first Vuori purchase. Follow Ali: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!

Michelle Andrews built a career inside the pharma machine long before anyone knew what “DTC” meant. She helped launch Rituxan and watched Allegra commercials teach America how to ask for pills by name. Then she landed in the cancer fun house herself, stage 4 breast cancer, and learned exactly how hollow all the “journey” slide decks feel when you're the one circling the drain.We talk about what happens when the insider becomes the customer, why pill organizers and wheat field brochures still piss her off, and how she fired doctors who couldn't handle her will to live. You'll hear about the dawn of pharma advertising, the pre-Google advocacy hustle, and what she wants every brand team to finally admit about patient experience.If you've ever wondered who decided windsurfing was the best way to sell allergy meds—or what happens when you stop caring if you make people uncomfortable—listen up.RELATED LINKSMichelle Andrews on LinkedInTrinity Life Sciences – Strategic AdvisoryJade Magazine – Ticking Time Bombs ArticleNIHCM Foundation – Breast Cancer StoryFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The incidence of early onset colorectal cancer (EOCRC) has been rising prompting the change in change in screening guidelines to 45 years of age for average risk patients. Join us for an in-depth discussion with guest speakers Dr. Andrea Cercek and Dr. Nancy You, where we provide a comprehensive look at the growing challenge of EOCRC. Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center - Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian - Dr. Phil Bauer, Graduating Colorectal Surgical Oncology Fellow at Memorial Sloan Kettering Cancer Center  - Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center - Dr. Andrea Cercek - Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center - Dr. Y. Nancy You, MD MHSc - Professor, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Learning objectives:  - Describe trends in incidence of colorectal cancer, with emphasis on the rise of EOCRC. - Identify age groups and demographics most affected by EOCRC. - Summarize USPSTF recommendations for colorectal cancer screening. - Distinguish between screening methods (e.g., colonoscopy, FIT-DNA) and their sensitivity. - Understand treatment approaches for colon and rectal cancer (CRC) - Understand the role of mismatch repair (MMR) status in guiding treatment. - Outline the importance of genetic counseling and testing in young patients. - Discuss racial, ethnic, and socioeconomic disparities in CRC incidence and outcomes. - Describe the impact of cancer treatment on fertility and sexual health. -  Review fertility preservation options. - Identify the value of integrated care teams for young CRC patients. References: 1.         Siegel, R. L. et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI J. Natl. Cancer Inst. 109, djw322 (2017). https://pubmed.ncbi.nlm.nih.gov/28376186/ 2.         Abboud, Y. et al. Rising Incidence and Mortality of Early-Onset Colorectal Cancer in Young Cohorts Associated with Delayed Diagnosis. Cancers 17, 1500 (2025). https://pubmed.ncbi.nlm.nih.gov/40361427/ 3.         Phang, R. et al. Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing? Asia Pac. J. Clin. Oncol.https://pubmed.ncbi.nlm.nih.gov/40384533/ 4.         Vitaloni, M. et al. Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries. BMC Gastroenterol. 25, 378 (2025). https://pubmed.ncbi.nlm.nih.gov/40375142/ 5.         Siegel, R. L. et al. Global patterns and trends in colorectal cancer incidence in young adults. (2019) doi:10.1136/gutjnl-2019-319511. https://pubmed.ncbi.nlm.nih.gov/31488504/ 6.         Cercek, A. et al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. J. Natl. Cancer Inst. 113, 1683–1692 (2021). https://pubmed.ncbi.nlm.nih.gov/34405229/ 7.         Zheng, X. et al. Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer. JNCI J. Natl. Cancer Inst. 113, 543–552 (2021). https://pubmed.ncbi.nlm.nih.gov/33136160/ 8.         Standl, E. & Schnell, O. Increased Risk of Cancer—An Integral Component of the Cardio–Renal–Metabolic Disease Cluster and Its Management. Cells 14, 564 (2025). https://pubmed.ncbi.nlm.nih.gov/40277890/ 9.         Muller, C., Ihionkhan, E., Stoffel, E. M. & Kupfer, S. S. Disparities in Early-Onset Colorectal Cancer. Cells 10, 1018 (2021). https://pubmed.ncbi.nlm.nih.gov/33925893/ 10.       US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 1965–1977 (2021). https://pubmed.ncbi.nlm.nih.gov/34003218/ 11.       Fwelo, P. et al. Differential Colorectal Cancer Mortality Across Racial and Ethnic Groups: Impact of Socioeconomic Status, Clinicopathology, and Treatment-Related Factors. Cancer Med. 14, e70612 (2025). https://pubmed.ncbi.nlm.nih.gov/40040375/ 12.       Lansdorp-Vogelaar, I. et al. Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer Rates. Cancer Epidemiol. Biomarkers Prev. 21, 728–736 (2012). https://pubmed.ncbi.nlm.nih.gov/22514249/ 13.       Ko, T. M. et al. Low neighborhood socioeconomic status is associated with poor outcomes in young adults with colorectal cancer. Surgery 176, 626–632 (2024). https://pubmed.ncbi.nlm.nih.gov/38972769/ 14.       Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA. Cancer J. Clin. 73, 233–254 (2023). https://pubmed.ncbi.nlm.nih.gov/36856579/ 15.       Jain, S., Maque, J., Galoosian, A., Osuna-Garcia, A. & May, F. P. Optimal Strategies for Colorectal Cancer Screening. Curr. Treat. Options Oncol. 23, 474–493 (2022). https://pubmed.ncbi.nlm.nih.gov/35316477/ 16.       Zauber, A. G. The Impact of Screening on Colorectal Cancer Mortality and Incidence: Has It Really Made a Difference? Dig. Dis. Sci. 60, 681–691 (2015). https://pubmed.ncbi.nlm.nih.gov/25740556/ 17.       Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116, 544–573 (2010). https://pubmed.ncbi.nlm.nih.gov/19998273/ 18.       Cercek, A. et al. Nonoperative Management of Mismatch Repair–Deficient Tumors. New England Journal of Medicine 392, 2297–2308 (2025). https://pubmed.ncbi.nlm.nih.gov/40293177/ 19.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Molecular Heterogeneity in Early-Onset Colorectal Cancer: Pathway-Specific Insights in High-Risk Populations. Cancers 17, 1325 (2025). https://pubmed.ncbi.nlm.nih.gov/40282501/ 20.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Ethnicity-Specific Molecular Alterations in MAPK and JAK/STAT Pathways in Early-Onset Colorectal Cancer. Cancers 17, 1093 (2025). https://pubmed.ncbi.nlm.nih.gov/40227607/ 21.       Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 19, 329–359 (2021). https://pubmed.ncbi.nlm.nih.gov/33724754/ 22.       Christenson, E. S. et al. Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/40388545/ 23.       Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet 402, 41–53 (2023). https://pubmed.ncbi.nlm.nih.gov/37331369/ 24.       Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). https://pubmed.ncbi.nlm.nih.gov/37142372/ 25.       Sauer, R. et al. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N. Engl. J. Med. 351, 1731–1740 (2004). https://pubmed.ncbi.nlm.nih.gov/15496622/ 26.       Cercek, A. et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 4, e180071 (2018). https://pubmed.ncbi.nlm.nih.gov/29566109/ 27.       Garcia-Aguilar, J. et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J. Clin. Oncol. 40, 2546–2556 (2022). https://pubmed.ncbi.nlm.nih.gov/35483010/ 28.       Schrag, D. et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N. Engl. J. Med. 389, 322–334 (2023). https://pubmed.ncbi.nlm.nih.gov/37272534/ 29.       Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A. & Dixon, J. M. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N. Engl. J. Med. 388, 585–594 (2023). https://pubmed.ncbi.nlm.nih.gov/36791159/ 30.       Jacobsen, R. L., Macpherson, C. F., Pflugeisen, B. M. & Johnson, R. H. Care Experience, by Site of Care, for Adolescents and Young Adults With Cancer. JCO Oncol. Pract. (2021) doi:10.1200/OP.20.00840. https://pubmed.ncbi.nlm.nih.gov/33566700/ 31.       Ruddy, K. J. et al. Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. J. Clin. Oncol. (2014) doi:10.1200/JCO.2013.52.8877. https://pubmed.ncbi.nlm.nih.gov/24567428/ 32.       Su, H. I. et al. Fertility Preservation in People With Cancer: ASCO Guideline Update. J. Clin. Oncol. 43, 1488–1515 (2025). https://pubmed.ncbi.nlm.nih.gov/40106739/ 33.       Smith, K. L., Gracia, C., Sokalska, A. & Moore, H. Advances in Fertility Preservation for Young Women With Cancer. Am. Soc. Clin. Oncol. Educ. Book 27–37 (2018) doi:10.1200/EDBK_208301. https://pubmed.ncbi.nlm.nih.gov/30231357/ 34.       Blumenfeld, Z. How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries. The Oncologist 12, 1044–1054 (2007). 35.       Bhagavath, B. The current and future state of surgery in reproductive endocrinology. Curr. Opin. Obstet. Gynecol. 34, 164 (2022). 36.       Ribeiro, R. et al. Uterine transposition: technique and a case report. Fertil. Steril. 108, 320-324.e1 (2017). 37.       Yazdani, A., Sweterlitsch, K. M., Kim, H., Flyckt, R. L. & Christianson, M. S. Surgical Innovations to Protect Fertility from Oncologic Pelvic Radiation Therapy: Ovarian Transposition and Uterine Fixation. J. Clin. Med. 13, 5577 (2024). 38.       Holowatyj, A. N., Eng, C. & Lewis, M. A. Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncol. Pract. 18, 169–172 (2022). ***Behind the Knife Colorectal Surgery Oral Board Audio Review: https://app.behindtheknife.org/course-details/colorectal-surgery-oral-board-audio-review Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Dr Tom Bird, Consultant Clinical Oncologist at Bristol Haematology and Oncology Center, UK, discusses how he treats people with oesophageal cancer.  This includes, locally advanced adenocarcinoma including staging, systemic and radiotherapy treatment, metastatic/recurrent adenocarcinoma (which includes an update on the treatment of gastric cancer treatment -alongside GOJ cancer -that we discussed in the prior gastric cancer podcast) including both systemic agents and palliative radiotherapy, and how treatment differs with squamous cell histology. This podcast is an overview of the current oncology treatment of oesophageal cancer at a registrar level and is aimed at those training in oncology in the UK. Your host is Dr Alison Cameron, Consultant Clinical Oncologist, Bristol, UK.

“The proteasome itself, it really helps us unfold or get rid of misfolded proteins or degradations of different cells. We used to have garbage disposals in our sinks, and we used to put food product in there. If your garbage disposal is clogged, then everything backs up. So that's kind of what's really going on in the cell itself, is that I'm building up these unnecessary proteins that we should be getting rid of, and it actually causes apoptosis or cell death,” ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the proteasome inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours (including 40 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 18, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of proteasome inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ Pharmacology 101 series ONS Voice article: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS Guidelines™ and Symptom Interventions Adherence to Oral Anticancer Medication Peripheral neuropathy ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Hematology International Myeloma Foundation Leukemia and Lymphoma Society Multiple Myeloma Research Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we look at the administration, we also want to make sure that we're looking at the blood counts, right? Because proteasome inhibitors are well known for causing thrombocytopenia and neutropenia. So making sure that the patients do meet eligibility for the treatment for that day, and do they have anemia or lower red blood cell counts. You want to make sure that, because of these therapies, that the patient has no symptoms or infections going into each therapy for that day.” TS 10:19 “[Bortezomib], interesting enough, it can cause hypotension, cardiac failure, and sometimes pulmonary edema. Switching that up a little bit, what makes it slightly different, carfilzomib … a lot of times we saw, even in the clinical trial, that there was a lot of hypertension or cardiomyopathies, or arrythmias that we saw with carfilzomib and different dosages that they have indicated from the FDA. So again, monitoring the hypertension … or heart failure.” TS 15:16 “We also want to keep in mind another adverse effect, and especially in myeloma—our patients come in the door already immunocompromised just by the disease state alone. But now I'm giving them therapies that can drop their neutrophil count, so neutropenia and thrombocytopenia, so they are at a higher risk of having serious infections, even including like pneumonia or having outbreaks of herpes zoster or shingles.” TS 16:50 “If the patient has shortness of breath or symptoms, hold the therapy. I think that's one of my biggest messages when it comes to cancer treatments and educating other healthcare providers, or even educating our patients and their caregivers or the care partners with them, is that we need to sometimes hold the therapy for safety.” TS 22:02 “I say keep a log, keep a book. Let me know when the symptoms happen. Are they happening the day of treatment? Are they happening two days later from the treatment? Are they happening a week later from the treatment? And being able to kind of guide which therapy is causing some of these adverse events or side effects alone. So, making them have calendars. When did you take the drug, when did you get your last infusion or your last [subcutaneous] injection? Always talk to your care team, whether it's in the academic center or next to your house in the community.” TS 26:17 “It's us learning how to listen to the patient going forward. We have tasks to do—we all have tasks to do in our lives—but we have to take a breath, be mindful who's in front of us, listen to them first, and then be able to talk to them and care for them upfront and see what the symptoms are. I think that's what we need to do. We have to take a breath in cancer.” TS 39:35

Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Scientists have uncovered a promising new strategy to weaken cancer cells' natural defense mechanisms, potentially making chemotherapy more effective. In a study published in Volume 16 of Oncotarget, researchers identified the protein PRDX1 as a key player in helping tumors resist treatment. By targeting this protein, they propose a novel way to combat aggressive, treatment-resistant cancers. Understanding Why Some Cancers Resist Treatment Chemotherapy works by damaging the DNA of cancer cells, forcing them to self-destruct. However, many cancers develop robust repair systems that fix this damage, allowing the tumor to survive and grow. A central component of this repair machinery is a protein called ATM, which acts like a first responder in the cell, detecting DNA damage and coordinating its repair. In ovarian cancer and other aggressive tumors, high levels of ATM have been associated with poor survival rates and resistance to chemotherapy. The Study: How PRDX1 Protects Cancer Cells The study, titled “PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling,” was led by first author Reem Ali and corresponding author Dindial Ramotar from Hamad Bin Khalifa University in Qatar, in collaboration with researchers from the University of Nottingham in the UK. Full blog - https://www.oncotarget.org/2025/07/14/prdx1-identified-as-key-to-chemotherapy-resistance-in-cancer-cells/ Paper DOI - https://doi.org/10.18632/oncotarget.28720 Correspondence to - Dindial Ramotar - dramotar@hbku.edu.qa Video short - https://www.youtube.com/watch?v=suOhF7mPlNQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28720 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, redox signaling, homologous recombination, protein interaction, cell cycle, protein modification To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

On this episode, Dr. Hadas Ofek discusses a new, mechanism-based therapeutic approach to ease symptoms of CIPN. Using both patient-reported measures and measures of physical function, her team assessed the feasibility and effectiveness of a short sensory retraining physiotherapy treatment course for individuals experiencing CIPN.

 Today on Beating Cancer Daily, Saranne welcomes back Jacqui Bryan to explore the crucial role of potassium in cancer recovery, athletic performance, and overall well-being. Jacqui draws from her own journey as a breast cancer survivor and discusses how potassium, as a key electrolyte, impacts heart function, muscle health, nerve signaling, and kidney function. Saranne and Jacqui break down how potassium balances with sodium in the diet, why maintaining healthy levels is especially important during chemotherapy, and how food choices can empower everyone, including those with Stage IV cancer, to feel more in control of their health. Jacqui Bryan is a certified nutrition specialist, whole health educator, certified health coach, and registered nurse. With over two decades of experience and a personal backstory of surviving breast cancer, Jacqui has become a trusted ally in the cancer community, guiding individuals toward whole-food nutrition and greater self-advocacy. Her extensive background makes her a sought-after resource for anyone seeking to optimize wellness during and after cancer treatment. "You are a whole person. You're not just potassium; you're not just sodium.  Everything's connected." ~Jacqui Bryan Today on Beating Cancer Daily:·     Potassium is vital for heart health, muscle and nerve function, blood pressure regulation, and kidney efficiency·     Chemotherapy can deplete potassium, making careful monitoring essential for those in cancer treatment·     Maintaining the balance between sodium and potassium is crucial for fluid and electrolyte stability·     Food sources—such as bananas, spinach, potatoes, dairy, fish, nuts, and beans—are the safest way to support potassium levels·     Symptoms of low potassium include dehydration, muscle weakness, heart palpitations, and headaches·     Potassium intake can lower the risk of stroke, enhance bone strength, and aid in preventing kidney stones·     Potassium's role in flushing fluid from cells can even improve the appearance of cellulite·     Supplements should only be considered under medical supervision, not as a first-line approach Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg!   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

Don't go looking for an early ticket to heaven and listen to God – life is precious! -------- Thank you for listening! Your support of Joni and Friends helps make this show possible.     Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org   Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textTalking to children about hair loss and cancer Lauren MacClain was diagnosed with breast cancer at 40, when her children were from 5-10 years old. Her and her husband wanted to find the best way to speak to their children about what would happen during her treatment, and found that the books that were available didn't quite explain different areas of treatment very well.Lauren had to wait over the xmas period to get her biopsy results, which was a scary time. After having a mastectomy, they found that it had spread to one of her lymph nodes which meant she needed to have chemotherapy.Lauren found out about scalp cooling whilst she was researching treatments and decided to try it, as she had been warned that the chemo she needed was very dose-dense and can cause permanent hair loss (PCIA). Because of this, she managed to retain around 50% of her hair, and it grew back quickly afterwards. She has now written 3 children's books explaining cold caps and chemotherapy treatment, to help families explain to their children what is going on in an easy way.Connect with Lauren:InstagramBooksPaxman scalp cooling Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy: Facebook Instagram Twitter Clubhouse- @Hair.Therapy Donate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert!

Originally aired in 2023, Molly Jacobson interviews Dr. Kim Agnew about the groundbreaking trials of Monepantel, a sheep dewormer repurposed as a potential treatment for canine lymphoma. Discover the science behind this innovative therapy, its potential to stabilize lymphoma, and how it compares to traditional treatments like chemotherapy and prednisone.  Key Topics:  What is Monepantel, and how was it discovered?  The mechanism behind Monepantel's ability to target cancer cells.  Early trial results: Quality of life and stability for dogs with B-cell lymphoma.  How Monepantel compares to prednisone and chemotherapy.  Insights into ongoing and future clinical trials.  How dog lovers can participate in studies.  Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question.   Related Videos:  https://www.youtube.com/watch?v=_92w6TTXM5c   https://www.youtube.com/watch?v=uAZrPM1X8ww   Related Links:  PharmAust Dog Lymphoma Clinical Trial: https://www.pharmaust.com/petdogtrial/  Chapters:  00:00 Introduction  00:30 Meet Dr. Kim Agnew and Monepantel Overview  01:15 The Origin of Monepantel: From Dewormer to Cancer Fighter  03:30 How Monepantel Targets Cancer Cells  07:00 Insights on Clinical Trials for Canine Lymphoma  09:30 Benefits of Monepantel: A Daily Pill for Dogs  12:00 Comparing Monepantel to Chemotherapy and Prednisone  14:45 Early Trial Results: Stabilizing Lymphoma in Dogs  18:30 Why Lymphoma Was Chosen for Trials  20:00 Potential for Treating Other Cancers in Dogs  23:15 How to Enroll Dogs in Clinical Trials  26:45 Side Effects and Safety of Monepantel  31:00 Future Trials and Research Goals  34:30 Closing Thoughts and Resources  33:55 Closing Remarks and Resources    Get to know Kim Agnew, BVSc: https://www.dogcancer.com/people/kim-agnew-bvsc/     For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

"Despite my insistence that 'I can do this,' and, 'I'm fine,' and, 'I've got this,' I don't got this without my people." I'm fresh off my second round of chemotherapy, and am back on the couch recording with friends. This time for chemo, I was joined by my dear friend Conor Nickel, and this is our recap from the day at the infusion center, and the few days we had together. We answered tons of listener questions, and Conor talks about being one of my go-to people throughout all of this.  SPONSOR:  New Balance: Click here to get your hands on the just-released Rebel v5! Follow Ali: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!

A quick trip to the surgeon reveals that all is not as it seems, and Ben's colon cancer journey takes a sharp turn almost as immediately as it starts. Multiple tumors during a surgery initially meant to remove a single cancerous mass lead to a diagnosis of metastasized colorectal cancer. And the expensive nuclear diagnosis machine shorts – in much the same way Ben's Father's brand new (at the time) Vauxhall Victor broke down on a Sunday afternoon drive. A potential podcast subject that Ben dismissed years ago as not being interesting enough (Italian data on a barrage of combination chemotherapy) reappears as the best first-line treatment option for Ben in 2025. The episode concludes with insights from Ben's oncologist and preparation for the rigorous chemotherapy regimen ahead: Chemotherapy – it's a full-time job. 00:00 Introduction: The Vauxhall Victor Story 02:11 Unexpected Medical News 04:12 Understanding the Diagnosis 06:45 The PET Scan Incident 11:04 Meeting the Oncologist 15:15 Preparing for Chemotherapy 16:58 Conclusion: The Journey Ahead https://www.mycrohnsandcolitisteam.com/ https://www.cancer.gov/types/colorectal https://www.cancer.org/cancer/types/colon-rectal-cancer.html

Program notes:0:40 A novel way to help aphasia after a stroke1:40 C7 nerve ligation2:42 Somatosensory function versus speech processing3:36 Substandard anticancer medications4:40 Tested many using HPLC5:40 Alarming that one in six is impacted6:40 Paying out of pocket7:38 New type of medicine for treatment resistant hypertension8:38 Need to follow electrolytes9:00 ED boarding for elderly10:00 Length of stay increased11:00 Elderly more likely to suffer complications12:00 CMS program for all inclusive care for elderly12:49 End

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textIt's a common scenario for a cancer patient. They're undergoing treatment and get what's known as a peripherally inserted central catheter or PICC (pronounced “pick”) line to make it more convenient to administer drugs. They are in and out of the hospital or just the clinic frequently to see various providers. The treatment they receive may run down their immune system a little bit. Just having cancer may have damaged their immune system.So then they get an infection.Perhaps it's no big deal. A round of antibiotics may take care of it. However, increasingly, these infections are resistant to antibiotics – something known as antimicrobial resistance or AMR.Then, the patient must wait weeks or even months to resume cancer treatment while the infection is treated. And, all too often, the infection itself may kill the patient. In fact, infections are the second-leading cause of death for cancer patients.Dr. Yehoda M. Martei, Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania, and colleagues have been working to find out just how common these infections are. Among patients hospitalized for treatment, cancer patients were up to twice as likely to get a drug-resistant infection, she and colleagues found. Among outpatients – people getting treatment at clinics or offices but not staying in the hospital – cancer patients had three times the risk of drug-resistant infections.Listen as Dr. Martei tells One World, One Health host Maggie Fox about her findings, what they mean, and what must be done to protect cancer patients and ensure infections don't stop them from getting the treatment they need.

Commentary by Mohamad Bassam Sonbol.

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

[01:03:01 – 01:04:09] — Outrage Over Unilateral Iran Strikes Hosts express shock and anger at Trump's decision to bomb Iran without congressional approval, predicting escalation and criticizing the move as instigative and unconstitutional.[01:04:11 – 01:08:06] — Strait of Hormuz Closure Threat and Economic Fallout Discussion centers on Iran's threat to close the Strait of Hormuz, highlighting the potential for oil price spikes and global economic disruption due to regional instability.[01:14:53 – 01:18:11] — Critique of Zionism's Influence on U.S. Christians Criticism is leveled at the influence of Zionism within American churches, claiming theological manipulation has led to uncritical support for Israel and military aggression.[01:33:12 – 01:35:06] — China Condemns U.S. Strike and Calls for Restraint China issues an official statement condemning U.S. strikes on Iran, urging all parties to de-escalate and uphold international law and nuclear safeguards.[01:36:42 – 01:39:03] — Russia Compares Iran Strike to Iraq Invasion Lies Russia denounces U.S. attacks as violating international law, likening them to the fabricated justifications for the Iraq War and warning of global nuclear consequences.[01:52:25 – 01:53:20] — Tel Aviv Thanks U.S. for Bombing Iran A clip from Tel Aviv shows public support for U.S. military actions, prompting sharp criticism of American complicity in destruction across the region.[02:02:03 – 02:04:14] — Church Shooting Sparks Push for Armed Congregations Following a church shooting in Michigan, Polk County's sheriff urges all houses of worship to adopt active shooter response plans and bolster security, reigniting debate on arming congregants.[02:05:00 – 02:13:04] — Critique of Chemotherapy and Praise for Alternative Cancer Therapies A personal account of loss is used to critique standard cancer treatments while promoting the Templeton Wellness Foundation and manuka honey as viable natural alternatives.[02:14:01 – 02:15:53] — Fasting, EMFs, and Environmental Cancer Triggers Highlights the role of metabolic health, EMF exposure, and nutrient-depleted food in rising cancer rates, with pets cited as early warning indicators due to increased tumor diagnoses.[02:22:20 – 02:26:20] — Ivermectin and Fenbendazole as Cancer Protocols Cites doctors promoting dewormers like ivermectin and fenbendazole for cancer treatment, warns against low-quality online sources, and suggests a Canadian supplier as more trustworthy.[02:37:01 – 02:41:41] — B-17, Apricot Seeds, and Cancer Suppression Discusses historical suppression of B-17/laetrile as a cancer treatment, citing G. Edward Griffin's advocacy and promoting apricot seeds as daily preventative immune support.[02:41:43 – 02:45:16] — Glyphosate, Chlorine Dioxide, and Toxic Synergy Condemns Monsanto/Bayer for seeking immunity from glyphosate liability and promotes chlorine dioxide as a controversial but potentially effective method for detoxifying glyphosate from the body.[02:58:54 – 03:15:47] — Grace Schara Trial Recap: Alleged Hospital Negligence and End-of-Life Protocols Details the lawsuit involving the death of Grace Schara, a disabled patient allegedly given unauthorized sedatives and a DNR without family consent, raising broader concerns over hospital protocols during COVID.[03:16:01 – 03:21:45] — Suspicious Death of AI Whistleblower Suchir Balaji Examines inconsistencies in the reported suicide of a former OpenAI employee who had exposed copyright violations and criticized leadership, including forensic anomalies and surveillance failures.[03:24:01 – 03:32:13] — Dangers of AI: Surveillance, Tyranny, and Societal Dependence A wide-ranging discussion highlights AI's integration into daily life, citing loss of privacy, data abuse, blackmail potential, and fears of centralized control over human behavior and services.[03:32:15 – 03:37:24] — Creative Destruction: AI's Threat to Art, Work, and Human Connection Critiques the replacement of human-created art and labor with AI-generated outputs, lamenting the erosion of creativity, spiritual meaning, and the intrinsic joy found in skill-building.[03:47:24 – 03:55:28] — Economic Collapse Forecast and Artificial Recovery Illusions Explains how artificial stock market inflation masks broader economic collapse, blaming monetary policy and war for destabilizing the dollar and projecting a future of bartering and hardship. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[01:03:01 – 01:04:09] — Outrage Over Unilateral Iran Strikes Hosts express shock and anger at Trump's decision to bomb Iran without congressional approval, predicting escalation and criticizing the move as instigative and unconstitutional.[01:04:11 – 01:08:06] — Strait of Hormuz Closure Threat and Economic Fallout Discussion centers on Iran's threat to close the Strait of Hormuz, highlighting the potential for oil price spikes and global economic disruption due to regional instability.[01:14:53 – 01:18:11] — Critique of Zionism's Influence on U.S. Christians Criticism is leveled at the influence of Zionism within American churches, claiming theological manipulation has led to uncritical support for Israel and military aggression.[01:33:12 – 01:35:06] — China Condemns U.S. Strike and Calls for Restraint China issues an official statement condemning U.S. strikes on Iran, urging all parties to de-escalate and uphold international law and nuclear safeguards.[01:36:42 – 01:39:03] — Russia Compares Iran Strike to Iraq Invasion Lies Russia denounces U.S. attacks as violating international law, likening them to the fabricated justifications for the Iraq War and warning of global nuclear consequences.[01:52:25 – 01:53:20] — Tel Aviv Thanks U.S. for Bombing Iran A clip from Tel Aviv shows public support for U.S. military actions, prompting sharp criticism of American complicity in destruction across the region.[02:02:03 – 02:04:14] — Church Shooting Sparks Push for Armed Congregations Following a church shooting in Michigan, Polk County's sheriff urges all houses of worship to adopt active shooter response plans and bolster security, reigniting debate on arming congregants.[02:05:00 – 02:13:04] — Critique of Chemotherapy and Praise for Alternative Cancer Therapies A personal account of loss is used to critique standard cancer treatments while promoting the Templeton Wellness Foundation and manuka honey as viable natural alternatives.[02:14:01 – 02:15:53] — Fasting, EMFs, and Environmental Cancer Triggers Highlights the role of metabolic health, EMF exposure, and nutrient-depleted food in rising cancer rates, with pets cited as early warning indicators due to increased tumor diagnoses.[02:22:20 – 02:26:20] — Ivermectin and Fenbendazole as Cancer Protocols Cites doctors promoting dewormers like ivermectin and fenbendazole for cancer treatment, warns against low-quality online sources, and suggests a Canadian supplier as more trustworthy.[02:37:01 – 02:41:41] — B-17, Apricot Seeds, and Cancer Suppression Discusses historical suppression of B-17/laetrile as a cancer treatment, citing G. Edward Griffin's advocacy and promoting apricot seeds as daily preventative immune support.[02:41:43 – 02:45:16] — Glyphosate, Chlorine Dioxide, and Toxic Synergy Condemns Monsanto/Bayer for seeking immunity from glyphosate liability and promotes chlorine dioxide as a controversial but potentially effective method for detoxifying glyphosate from the body.[02:58:54 – 03:15:47] — Grace Schara Trial Recap: Alleged Hospital Negligence and End-of-Life Protocols Details the lawsuit involving the death of Grace Schara, a disabled patient allegedly given unauthorized sedatives and a DNR without family consent, raising broader concerns over hospital protocols during COVID.[03:16:01 – 03:21:45] — Suspicious Death of AI Whistleblower Suchir Balaji Examines inconsistencies in the reported suicide of a former OpenAI employee who had exposed copyright violations and criticized leadership, including forensic anomalies and surveillance failures.[03:24:01 – 03:32:13] — Dangers of AI: Surveillance, Tyranny, and Societal Dependence A wide-ranging discussion highlights AI's integration into daily life, citing loss of privacy, data abuse, blackmail potential, and fears of centralized control over human behavior and services.[03:32:15 – 03:37:24] — Creative Destruction: AI's Threat to Art, Work, and Human Connection Critiques the replacement of human-created art and labor with AI-generated outputs, lamenting the erosion of creativity, spiritual meaning, and the intrinsic joy found in skill-building.[03:47:24 – 03:55:28] — Economic Collapse Forecast and Artificial Recovery Illusions Explains how artificial stock market inflation masks broader economic collapse, blaming monetary policy and war for destabilizing the dollar and projecting a future of bartering and hardship. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When your doctor says you need “cancer treatment,” do you know what that actually means?Most people immediately think of chemotherapy. But if you or someone you love is facing a cancer diagnosis, understanding the full range of treatment options could be the difference between feeling overwhelmed and feeling empowered.Dr. Katie Deming sits down with Dr. Jason Konner, a medical oncologist at Memorial Sloan Kettering Cancer Center, to break down the three main types of systemic cancer treatment used today: chemotherapy, targeted therapies, and immunotherapies.Chapters:03:43 – Three Main Types of Cancer Treatment16:34 – Why First-Line Therapies Matter20:48 – Combining Holistic and Conventional Care31:23 – Essential Questions to Ask Your Oncologist43:42 – When and Why to Seek a Second OpinionDr. Konnor shares the insider perspective on second opinions, what those complex drug names really mean, and how to build the kind of relationship with your medical team that leads to better outcomes.You'll learn how some patients unknowingly sabotage their own care and what questions can instantly make you a more informed patient. Listen and learn how to walk into any oncologist's office with confidence, ask the right questions, and truly understand your options.Don't let medical jargon and complex choices keep you in the dark when clear thinking matters most.Reserve Your Spot for the June PSYCH-K® Online Workshop: https://www.katiedeming.com/psych-k-june-2025 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/ Work with Dr. Katie: www.katiedeming.comEmail: INFO@KATIEDEMING.COM 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

How do the experts balance organ preservation, oncologic control, and emerging therapies in both localized and metastatic cases of penile cancer? This episode of BackTable Tumor Board focuses on penile cancer diagnosis and treatment, featuring urologic oncologist Dr. Charles Peyton (UAB), radiation oncologist Dr. Juanita Crook (UBC), and medical oncologist Dr. Andrea Apolo (NCI). --- This podcast is supported by:Ferring Pharmaceuticals --- SYNPOSIS This session covers case studies ranging from localized to advanced penile cancer, diagnostic practices, imaging preferences (MRI vs. CT), and treatment options, including surgery, brachytherapy, chemoradiation, and neoadjuvant chemotherapy. The multidisciplinary team highlights the complexities of treating this rare cancer, underscores the importance of physical exams, and stresses the necessity of personalized treatment plans. They also delve into the challenges of managing metastatic stages, potential salvage therapies, and the importance of clinical trials in enhancing treatment efficacy. The doctors also emphasize the potential of immunotherapy and chemotherapy combinations for metastatic disease. --- TIMESTAMPS 00:00 - Introduction02:23 - Imaging Preferences03:29 - Biopsy vs Immediate Surgery06:04 - Lymph Node Dissection vs Radiation13:48 - Brachytherapy Techniques and Case Study23:21 - Challenges in Advanced Penile Cancer27:03 - Chemotherapy and Chemoradiation30:15 - InPACT Trial37:12 - Salvage Therapies and Exploring New Treatment Frontiers44:25 - Support and Awareness for Penile Cancer51:29 - Final Thoughts --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

  Hello, and welcome to episode 175 of the Childless Not by Choice Podcast. My name is Civilla Morgan. My mission is to recognize and speak to childless women and men not by choice worldwide, reminding us that we can live joyful, relevant, and fulfilled lives, childless by choice.   Whether you have children or not, thank you for tuning in!     What is today's show about? Father's Day and Men's Health   Thank you, Patreon contributors: I would like to thank my Patreon contributors, who support the platform every month.    Your contributions help me pay my podcast producer, my podcast host, Zoom, where I interview most of my guests, and other expenses. Thank you very much!        If you are not yet a Patron, visit patreon.com/childlessnotbychoice to set up your monthly contribution. No matter your giving level, I have a gift for you!   If you prefer to give via PayPal, you can find me there at booksbycivillamorgan@gmail.com.  Your contributions to the platform are greatly appreciated! Thank you!   https://www.patreon.com/Childlessnotbychoice   Questions or comments? Contact me at:   Email: Info@civillamorgan.com                                                  Or   Visit the website at www.childlessnotbychoice.net, look to the left on the home screen, and click on the link below the telephone to leave me an up to 90-second voicemail. Body of episode: FATHER'S DAY  MEN'S HEALTH  So, well before President Biden's prostate cancer diagnosis, I had planned on discussing men's health for this year's Father's Day episode. In particular, I wanted to discuss causes of male childlessness, such as Azoospermia.  I've decided to put links in the show notes in regards to Azoospermia. Please check out the links for further information.  The basic definition of Azoospermia per The Cleveland Clinic website is:   ‘Azoospermia means there's no sperm in your ejaculate. Its causes include a blockage along the reproductive tract, hormonal problems, ejaculation problems or issues with testicular structure or function. Many causes are treatable. For other causes, it may be possible to retrieve live sperm to be used in assisted reproductive techniques like IVF.‘    As I think back through my episodes, I don't believe I've ever discussed men's health, or medical reasons men may be childless.  We've discussed fibroids, PCOS, endometriosis, adenomyosis, miscarriage, running out of time, aka the biological clock, MRKH, etc.  But I've never gone into much detail regarding issues surrounding the causes of childlessness in men.    I have had the great opportunity to interview several men about their experiences with childlessness, including how they have dealt with it. I will put links in the show notes on interviews I have conducted over the years with these wonderful men. Be sure to take a listen!    I also believe male childlessness is not as openly discussed as female childlessness because men and their spouses may find the issue embarrassing, shocking to their ego in a different way than a woman may feel about her childlessness, or maybe in much the same way.  In either case, there can be emotional and mental pain.    Some of the things that can cause infertility in men include:   AI Overview Male infertility can be caused by a variety of factors, including problems with sperm production or quality, hormonal imbalances, genetic disorders, infections, and environmental factors. Additionally, lifestyle choices like smoking, excessive alcohol consumption, and certain drug use can also contribute to infertility.  Here's a more detailed look at some of the key causes: 1. Sperm Problems: Low sperm count (oligospermia): A low number of sperm in the ejaculate. Absent sperm (azoospermia): No sperm in the ejaculate. Poor sperm motility: Sperm are unable to swim properly. Abnormal sperm morphology: Sperm are abnormally shaped, making it difficult for them to fertilize an egg.  2. Hormonal Imbalances:  Reduced testosterone: Low levels of testosterone can affect sperm production.  Hyperprolactinemia: Elevated levels of prolactin can interfere with sperm production.  Hormonal disorders affecting the pituitary gland or hypothalamus: These glands regulate hormone production.  3. Genetic Disorders: Klinefelter syndrome: A genetic condition affecting males. Cystic fibrosis: A genetic disorder that can cause blocked reproductive ducts. Myotonic dystrophy: A genetic disorder that can affect sperm production.  4. Infections and Inflammation: Epididymitis: Inflammation of the epididymis, the tube that carries sperm from the testicles.  Orchitis: Inflammation of the testicles.  STIs: Sexually transmitted infections like gonorrhea or chlamydia can cause inflammation and damage to the reproductive organs.  5. Environmental and Lifestyle Factors: Smoking: Smoking can reduce sperm count and quality.  Alcohol consumption: Excessive alcohol use can lower testosterone levels and affect sperm production.  Certain drug use: Anabolic steroids and other drugs can negatively impact sperm production.  Exposure to toxins or chemicals: Exposure to certain toxins, like pesticides, can affect fertility.  Obesity: Being overweight or obese can impact sperm quality.  6. Medical Conditions: Diabetes: Diabetes can affect sperm production and quality. Kidney failure: Kidney failure can also impact sperm production. Cystic fibrosis: A genetic disorder that can cause blocked reproductive ducts. Autoimmune diseases: Some autoimmune diseases can attack sperm.  7. Other Factors: Varicocele: Enlarged veins in the scrotum, which can raise testicular temperature and affect sperm production.  Testicular trauma: Injury to the testicles can damage sperm production.  Previous cancer treatment: Chemotherapy and radiation therapy can affect sperm production.  Undescended testicles: Testicles that don't descend into the scrotum.  Blockages or absences of tubes: Blockages in the reproductive tract can prevent sperm from being released.  This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Whether you have children or not, your health is important. Be sure to go to all of your check-ups, especially if there is a family history of health issues. Get checked, don't wait.   Be OK with advocating for yourself. The healthcare industry may say no, you are too young for a particular test. But if you want that test, be insistent. Keep in mind that if your insurance does not cover the test because you are not of a certain age or whatever their parameters are, you may have to pay out of pocket.   Happy Father's Day to all the wonderful men out there who do the work of raising great people for this world.  Happy Father's Day to those of you who did not birth children, but are contributing to a child's life in beautiful and lasting ways.         Research links:   https://my.clevelandclinic.org/health/diseases/15441-azoospermia Articles/links of interest: https://ifstudies.org/blog/pronatalism-is-not-popular-yet Episode links to conversations with men: https://childlessnotbychoice.net/episode-143-the-things-men-talk-about-my-conversation-with-dr-robin-hadley/ https://childlessnotbychoice.net/episode-116-my-conversation-with-dave-jackson/ https://childlessnotbychoice.net/episode-141-downriver-nomad-my-conversation-with-rob-hutchings/ https://childlessnotbychoice.net/episode-130-about-fathers-day-and-childlessness/ https://childlessnotbychoice.net/episode-57-men-men-men-men-3/ My contact information: Website: www.childlessnotbychoice.net and www.civillamorgan.com Facebook: booksbycivillamorgan Instagram: @joyandrelevance Pinterest: Civilla M. Morgan, MSM LinkedIn: Civilla Morgan, MSM  

Episode 367: Pharmacology 101: PARP Inhibitors “We know that in cells that are proliferating very quickly, including cancer cells, single-strand DNA breaks are very common. When that happens, these breaks are often repaired by the PARP enzyme, and the cells can continue their replication process. If we block PARP, that repair cannot happen. So in blocking that, these single-strand breaks then lead to double-strand breaks, which ultimately is leading to cell apoptosis,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the PARP inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 13, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of PARP inhibitors in cancer care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 232: Managing Fatigue During PARP Inhibitor Maintenance Therapy Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Maintenance Therapy ONS Voice articles: PARP Inhibitors and Ovarian Cancer Genomics May Trick PARP Inhibitors to Treat More Cancers Oncology Drug Reference Sheet: Niraparib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing articles: PARP Inhibition: Genomics-Informed Care for Patients With Malignancies Driven by BRCA1/BRCA2 Pathogenic Variants Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers Oncology Nursing Forum article: Familiarity and Perceptions of Ovarian Cancer Biomarker Testing and Targeted Therapy: A Survey of Oncology Nurses in the United States Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Biomarker Database ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The big toxicities here to watch for are primarily hematologic toxicities. It is one of those targeted therapies that does affect blood cell counts. So I'd say the blood cell count that is most commonly affected here is the hemoglobin. So, anemia very frequent complication that we see, probably a little bit more with olaparib compared with other drugs, but we see it as a class side effect. And we can also see neutropenia and thrombocytopenia with these agents, probably a little bit more with niraparib versus the others, but again, you can see it across all of these drugs.” TS 8:16 “We mentioned that rare risk of MDS and AML. This isn't a particularly scary thing if you talk to patients about it. Because of the rarity that we see this, it isn't something that we need to overemphasize, but I think careful monitoring of blood counts in is stressing the importance of that and early intervention here is very important.” TS 16:55 “This is a collaborative effort. And because of the home administration here, these patients do need to be followed very closely. So we are not laying eyes on them usually with the frequency that we do when we have patients actually coming into our infusion centers for treatments—so making sure that there is a plan for regular follow-up with these patients to ensure that they're getting that lab work done, that that's being looked at closely, that we're adjusting the dose if we need to based on that lab work, that we are managing the patient's fatigue. Again, that potentially dose reductions may be needed if patients are having that extreme fatigue.” TS 19:34 “I think one of those [misconceptions] could be that they're only effective in patients that have that BRCA1/2 mutation. And again, remember here that there is some data in particular disease states that we can use them and that they work in the absence of those mutations.” TS 25:12

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textPermanent Chemotherapy induced Hair loss ~ What you're not being told Shirley Ledlie was diagnosed with invasive breast cancer in 2005. She had a lumpectomy and node biopsy, and was told it had spread but the node was encapsulated. She had radiotherapy and chemotherapy with Taxoter. After her treatment, she noticed that her hair was not growing back. Her oncologist contacted the drug company, and they were aware that the treatment could cause permanent hair loss.It was then that she found out about PCIA. She has not had no hair for 20 years, and has a daily reminder of her cancer and her treatment.We discuss her story, and how permanent hair loss from Taxoter could be a lot more common than reported, and could be as high as 20-30%.Connect With Shirley:InstagramBookWebsite Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy: Facebook Instagram Twitter Clubhouse- @Hair.Therapy Donate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert!

Keeping the Prostate healthy is important as men age.  Prostate Cancer is the #1 Cancer in Men, which includes "almost all men over the age of 80".  In this episode, you'll discover:—How keeping your Testosterone levels up can help prevent Prostate Cancer.  And why Dr. Prather believes men don't "completely function well" outside of Prostate numbers in the 800-900 range. —The Benign Prostatic Hypertrophy (BPH) condition that creates an enlargement of the Prostate and is caused by Estrogen dominance. —The reason Dr. Prather was not surprised to hear that former President Joe Biden had Prostate Cancer.  And why he would not be surprised if President Donald Trump has it, too. —Why Diet, particularly increased Fiber, and Exercise are so important for Prostate Health.  And why it's important to eliminate toxins like heavy metals, infections, and parasites that can kick off Cancer in the body.—How a Native American herbal formula first developed by Hiawatha is still used by Dr. Prather for his patients to help detox the body.  And why Dr. Prather says that it's something "almost everyone who has Cancer should be taking".—The Vitamins, Minerals, Herbals, and Homeopathics that are most helpful for Prostate health and for lowering side-effects from Chemotherapy.  And how the Prostate contains the highest concentration of Zinc in the human body and is "critical" for Prostate health.—Why Dr. Prather predicts this generation of young men will have increased rates of Prostate Cancer due to Marijuana use. —The instantaneous relief Acupuncture provides for those suffering from Prostatitis.  And why you shouldn't be afraid of where Dr. Prather puts the needles! —The amazing story of a terminal Prostate Cancer patient sent by his oncologist to Dr. Prather for pain relief through Acupuncture.  And why the oncologist called to ask what Dr. Prather was doing to the patient after seeing the patient's PSA numbers plummet. —How just preventing a patient from becoming Anemic during Cancer treatment can increase their survival chances by 50%.  And how keeping the Liver clean during Cancer treatment can increase their chance of survival by another 25%.http://www.TheVoiceOfHealthRadio.com

      Guy Nakoa has survived two diagnoses of Stage IV breast cancer.  He initially felt a lump in his breast while showering in 2000.  Because it wasn't causing him and because he didn't think could not get a type of cancer associated with women, I went more than a decade before he chose to have the lump checked out.  In 2014, he sought medical attention, he was diagnosed and in 2016, he had the lump removed; but in 2020, the cancer returned.  He was hoping it could be removed with chemotherapy and radiation treatment, but over his initial objection, he agreed to a mastectomy of his left breast in 2024.  For the rest of his life, he will need to be on two medications, ibrance and letrozole.  Guy says from time to time he experiences fatigue but is very happy to be alive.   Guy Nakoa is from Wailuku on the island of Maui in Hawaii, but he has worked all over the world as a chef.  He was on a job in Alaska in 2000, when while taking a shower, he was shocked to feel a lump in his left breast.  Guy didn't tell anyone about it because it wasn't causing him any pain, and he felt too embarrassed to admit he may have a type of cancer that is generally associated with women.    He finally decided to have the lump examined in 2014.  His doctor didn't seem to think there was anything cancerous and told Guy not to worry about it.  Guy was misdiagnosed and he believes that, like he was, his doctor might have had difficulty connecting the lump with cancer because Guy is male.  Guy went to another doctor, and in 2016, he underwent a biopsy, which revealed he had breast cancer.    Guy Nakoa had the lump removed in 2016.  He underwent a chemotherapy regimen in 2017 and again in 2018.  He says he lost his sense of taste, his anxiety level went “through the roof” and he had a tough time getting to sleep.   The surgery was a success, but in 2020, the cancer returned.  Guy wanted to again treat it with chemotherapy and radiation, but his doctor urged him to get the breast removed.  Guy eventually relented and the mastectomy took place in 2024.   Guy says these days, he can do just about anything he could do before he first felt the lump, but fatigue sometimes sets in, in a way it didn't prior to his diagnosis.  By way of advice, he is quite adamant that, regardless of what seems irregular, if you notice something, anything abnormal about your health, to immediately seek medical attention.   Additional Resources:   Support Groups:   The Male Breast Cancer Global Alliance  https://www.mbcglobalalliance.org   Man Up To Cancer  https://www.manuptocancer.org   HIS Breast Cancer Awareness  https://www.hisbreastcancer.org      

Download the Cancer Metabolic Tracker hereCheck out the Total Gut Restore courseWebsite with all the things mentionedExploring Cancer as an Adaptation: Natural Approaches and Key Questions AnsweredIn this episode, the host delves into the concept of cancer as an adaptation rather than a disease, continuing from a previous discussion. The episode answers five common questions about cancer treatment: natural support for tumor shrinkage during chemotherapy, whether chemotherapy can cause more cancer, the true meaning of 'cure', the potential role of parasites in cancer, and the impact of pesticides on cancer risk. The host emphasizes the importance of an integrative approach, including fasting, optimal timing of chemotherapy, immune support, diet, and maintaining a non-hospitable internal terrain for cancer growth. The discussion also covers the controversy around chemotherapy, the importance of gut health, and the relevance of detoxification and antioxidants in cancer management.00:00 Introduction and Overview00:31 Addressing Common Cancer Questions03:37 Natural Support for Tumor Shrinkage14:56 Chemotherapy and Secondary Cancer Risks18:28 Understanding the Concept of 'Cure'23:42 Parasites and Cancer Connection29:50 Impact of Pesticides on Cancer Risk39:12 Conclusion and Final Thoughts

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Routine checkups aren't supposed to flip your world upside down. But for Korrie Medina, they did. In this episode, Lyndsay Soprano sits down with Korrie to talk about what it means to keep living your life while battling cancer.Korrie opens up about the shock of her diagnosis, the rollercoaster of treatments—chemo, radiation, brachytherapy—and the way cancer doesn't just touch your body, but everything: your mind, your relationships, your career. Lyndsay shares her own story too—what it's like to go through the medical system, the emotional fallout, and how women are so often expected to just keep going no matter how brutal it gets.They talk about the messiness of it all—how cancer can change your life in a heartbeat, how asking for help feels like a risk, and how it's easy to lose yourself in the chaos. But they also talk about strength: how to hold on to joy, to find moments of light, and to keep moving forward even when you're running on fumes.This episode is real, raw, and a reminder that no matter what you're going through, you're allowed to take up space and put yourself first.Find Korrie Medina Online Here:Instagram: @korrieanneFacebook: Korrie MedinaFind The Pain Game Podcast Online Here:Website: thepaingamepodcast.comInstagram: @thepaingamepodcastFacebook: The Pain Game PodcastLinkedIn: Lyndsay SopranoYouTube: The Pain Game PodcastEpisode Highlights:(00:00) Introduction to Chronic Pain and Trauma(03:19) Cervical Cancer Diagnosis Journey(04:07) Understanding Cancer Staging and Treatment Options(10:08) The Hybrid Approach to Healing(12:33) Chemotherapy Experience and Its Effects(18:12) Emergency Surgery and Its Complications(23:27) The Importance of Mindset in Healing(25:19) Embracing Happiness Amidst Struggles(26:18) The Mind-Body-Soul Connection(27:39) Navigating the Aftermath of Treatment(28:38) Understanding Brachytherapy(30:36) The Brutality of Medical Procedures(31:32) The Aftereffects of Radiation(33:45) The Reality of Menopause(35:45) Hormonal Imbalance and Mental Health(37:40) Reaching a Breaking Point(39:09) Seeking Help in Crisis(41:31) Reflections from the Psych Ward(43:40) The Importance of Self-Care(45:49) Empowering Women Through Adversity

BUFFALO, NY - June 3, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 19, 2025, titled “PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling." In this study, led by first author Reem Ali and corresponding author Dindial Ramotar from Hamad Bin Khalifa University in Qatar, researchers discovered that a protein called PRDX1 helps maintain the stability of ATM, a key protein involved in repairing damaged DNA, especially when cells are under stress from arsenite exposure. The study found that without PRDX1, cells lose their ability to repair DNA and become more sensitive to chemotherapy. This finding suggests that targeting PRDX1 could improve the success of some cancer treatments. PRDX1 is already known for its role in protecting cells from oxidative damage, but this study shows it also plays a role in the DNA repair process. ATM is an essential protein that detects breaks in DNA and starts the repair process. When PRDX1 is missing, ATM is rapidly lost, especially when cells are exposed to arsenite, a toxic substance found in the environment. Without ATM, the DNA repair system fails, leaving cells more vulnerable to damage. By using both human cell lines and clinical samples from ovarian cancer patients, the team showed that high levels of PRDX1, along with ATM and MRE11 (another DNA repair protein), were linked to tumors' aggressive features and lower patient survival rates. This pattern suggests that tumors with high PRDX1 may resist chemotherapy by increasing their DNA repair capacity. On the other hand, removing PRDX1 weakened the repair system and made cancer cells more responsive to DNA-damaging platinum drugs. The study also showed that combining low doses of arsenite with drugs that either block ATM or damage DNA caused a much higher rate of cancer cell death in cells that lacked PRDX1. These results suggest a new treatment approach: lowering PRDX1 levels to make cancer cells more sensitive to DNA-damaging platinum therapies already in use. This highlights PRDX1 not only as a protector of cell function but also as a potential weak point in cancer cells. “As such, we propose that small molecule inhibitors of PRDX1, or single nucleotide polymorphisms that compromise PRDX1 function, in combination with low doses of arsenite can be exploited to treat chemo-resistant tumours.” These findings open the door for the use of PRDX1 as a biomarker to predict treatment response and as a promising target for new combination therapies. For patients with ovarian cancer and potentially other tumors, adjusting PRDX1 levels may help overcome drug resistance and improve outcomes. DOI - https://doi.org/10.18632/oncotarget.28720 Correspondence to: Dindial Ramotar - dramotar@hbku.edu.qa Video short - https://www.youtube.com/watch?v=suOhF7mPlNQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28720 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, redox signaling, homologous recombination, protein interaction, cell cycle, protein modification To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

EXCLUSIVE: 'Baywatch' Pin-Up Nicole Eggert's Brutal Cancer Fight Comeback Revealed in Full - Including Mastectomy, Chemotherapy and Radiation TherapyAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

JCO Editorial Fellow Dr. Peter Li and JCO Associate Editor Dr. Andrew Ko discuss the ASCO 25 Simultaneous Publication paper "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Peter Li: Hello, everyone, and welcome to our 2025 ASCO Annual Meeting Series where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's meeting. I'm your host, Dr. Peter Li, JCO Editorial Fellow, and I'm joined by Dr. Andrew Ko, JCO Associate Editor, to discuss the Journal of Clinical Oncology article and abstract presentation "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Now, let's start off with the relevance of this article. Andrew, can you please explain this to our listeners? Dr. Andrew Ko: Sure. Thanks, Peter. So, this was a very large international study evaluating the combination of lenvatinib and pembrolizumab. And just for context, that combination has been approved for use in other solid tumor types. It's FDA approved for renal cell carcinoma, for example, and endometrial carcinoma. But this study was looking specifically at this combination together with a chemotherapy backbone - so either FOLFOX or CAPOX - and comparing that to what at the time was a standard of care, which was just standard chemotherapy by itself. So, this very large study was intending to look at this particular novel combination. And we can get into some of the nuances of this study because the way that the experimental, the combination arm, was designed was perhaps a little bit more on the unusual side and led to maybe some imbalance in terms of how we think about the respective arms. Dr. Peter Li: Okay. We can definitely talk more about that as we go on. So, what are some of the key results of this study, and how do you think this will impact practice in the future? Dr. Andrew Ko: That's a good question. Technically, it was not a positive study. Well, it was positive in the sense that the co-primary endpoints - which included both progression-free survival and overall survival - so, progression-free survival, it did technically meet its endpoint, both in terms of the overall population and the preplanned subgroup analysis of patients who had a PD-L1 CPS of greater than or equal to 1. So, there was a PFS benefit with the experimental combination - the lenvatinib, pembrolizumab, plus chemotherapy - compared to chemotherapy alone. I will say the benefit was on the more modest side. So, if you even look at the medians, it was not a marked difference. If you look at the hazard ratios, they did meet statistical significance. On the other hand, this did not translate into a benefit for overall survival. So, when you ask, "Well, is this going to inform practice?" I'd have to say no. It highlights, I think, that JCO does want to publish articles that aren't necessarily going to be practice-changing, but that I think offer a lot of insights into trial design and important aspects of investigating novel treatments, even if they don't end up moving the needle in routine clinical practice. Dr. Peter Li: I totally agree with you. I mean, it was significant in terms of progression-free survival, but again, not clinically significant. And then overall survival, the interventional arm actually appeared to do slightly worse overall. Can you make some comments on the strengths and the weaknesses of this study, and where do you see us going from here? Dr. Andrew Ko: So, I think a couple of things worth highlighting in this study, very well designed, more than 800 patients in total. So, first of all, as I mentioned at the beginning, the combination was a little bit unique in terms of patients enrolled to the experimental arm got the combination of lenvatinib, pembrolizumab, together with chemotherapy for a very finite duration. So, that period of chemotherapy they received was only three months. And per protocol, patients then just segued to, quote unquote “maintenance treatment” with just the lenvatinib and pembrolizumab combination. Whereas patients on the control arm, meaning chemotherapy alone, would continue chemotherapy basically in perpetuity until their disease progressed or intolerable toxicity. So, there really was an imbalance in terms of, if you think that chemotherapy or continuing chemotherapy beyond that initial three-month period of time may be significant, that could have had some impact on the robustness or the efficacy of the experimental arm. There were some other aspects in terms of perhaps some differences in the rates of post-progression treatment, in other words, patients going on to receive second-line treatment. I think the other very relevant aspect, Peter, in this study was that the control arm - and no fault of the investigators - but the control arm at the time the study was ongoing just consisted of chemotherapy, FOLFOX CAPOX, by itself, without an immune checkpoint inhibitor, right? And we clearly know, based on results of several large phase III studies, and it's now in standard clinical practice, that we routinely use chemotherapy plus an immune checkpoint inhibitor. Certainly for patients with CPS PD-1/PD-L1 scores that are, well, you could argue greater than 1, or perhaps greater than 5 or 10. But the point being that the control arm of the study probably doesn't reflect what is currently used in clinical practice. And that's just always a challenge in clinical trial design, right? That when a study is designed and when it rolls out, you're always at risk in a rapidly changing and moving field that the standard of care may evolve during the lifetime of that particular trial, which is what I think you see in LEAP-015. Dr. Peter Li: Totally understand. And the survival we see from this study is also roughly similar to the combination of immuno-chemotherapy that is the standard of care today, which is, the authors mentioned, 12 to 14 months. Thank you so much, Andrew, for your input and for speaking about the JCO article "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Join us again for the latest simultaneous publications from the 2025 ASCO Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

- Broadcast News Introduction and Upcoming Segments (0:00) - AI Advancements and Their Impact on Jobs (0:45) - Breaking News: Trump-China Trade Deal and Its Implications (2:46) - Pakistan-India Cyber War and Its Potential Escalation (9:55) - Power Grid Vulnerabilities and Preparedness (13:36) - Crypto Wallets and the Importance of Self-Custody (19:04) - AI Capabilities and Their Implications for Human Jobs (25:14) - The Role of Enoch AI in Empowering Users (59:30) - The War on Human Cognition and Its Vectors (1:05:29) - Strategies for Protecting Cognitive Function (1:21:34) - Chemotherapy and Cognitive Impairment (1:21:56) - Natural Light and Sun Exposure (1:25:06) - Media and Information Warfare (1:30:33) - Societal and Behavioral Factors (1:33:37) - Defending Against Environmental Toxins (1:41:05) - Nutritional and Dietary Factors (1:47:00) - Pharmaceutical and Medical Warfare (1:49:22) - EMF Exposure and Technological Risks (1:59:51) - Information Warfare and Censorship (2:02:12) - Societal and Behavioral Factors (2:11:11) - Zionist and Chinese Strategic Moves in the Middle East (2:25:45) - Trump's Arrogance and Military Presence in Panama (2:26:04) - China's Influence and Economic Strategy in Panama (2:26:21) - Strategic Importance of the Panama Canal (2:52:23) - Strait of Hormuz and Global Energy Supply (3:06:20) - US-China Trade War and Economic Implications (3:14:03) - Anthropological Warfare and Cultural Resilience (3:14:21) - Migration and Demographic Warfare (3:22:15) - Global Economic and Political Dynamics (3:28:51) - Future Strategic Moves and Predictions (3:33:17) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Episode Summary: In the beatitudes, Jesus paints a portrait of spiritual vitality and health into which Christ's kingdom members are being transformed. But at the root of that transformation process is cutting out the cancer of sin. Such excision of sin requires both confessing it, the first beatitude, and grieving over it, the second beatitude. The combination of these two attitudes is called repentance. The problem is that Christians can be lured into a kind of shallow, incomplete repentance that is destructive. It might be compared to surgery to remove the cancerous tumor that misses part of the tumor. Paul calls it “worldly sorrow that leads to death.” In contrast, says Paul, is “godly sorrow leading to repentance.” This godly sorrow corresponds to getting all the tumor and then using chemotherapy to destroy what is microscopic and missed. This kind of sorrow is the heart attitude Jesus refers to in the second beatitude. “Blessed are those who mourn, for they shall be comforted.” It is an attitude that is exhibited by David. It is described in unmistakable detail in Psalm 51, which he wrote after being confronted with his sin of adultery with Bathsheba and murder of her husband, Uriah. It is chemotherapy for sin.For Further Prayerful Thought: How would you defend the argument that confessing our sins is not enough; we need to grieve over them.What most stood out to you about David's confession of his sin in Psalm 51?How does Jesus' claim to be the messianic suffering servant whose ministry is described in Isaiah 61 show that his mission goes beyond going to the cross so we could be forgiven for our sins? What clues in Isaiah 61 and the second beatitude point to Jesus' current work of restoration—fixing whatever was broken by sin?For the printed version of this message click here.For a summary of topics addressed by podcast series, click here.For FREE downloadable studies on men's issues click here.To make an online contribution to enable others to hear about the podcast: (Click link and scroll down to bottom left)

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it's a really good marker because it's found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the MET inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to MET inhibitors. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Capmatinib Oncology Drug Reference Sheet: Tepotinib Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) Telephone Triage for Oncology Nurses (third edition) ONS courses: Safe Handling Basics ONS Biomarker Database ONS Huddle Cards: Monoclonal Antibodies Targeted Therapy ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets IV Chemotherapy Education Sheets Drugs@FDA To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The MET receptor was actually identified back in 1984. And it was actually identified as an oncogene in osteosarcoma. And so basically what that MET receptor does—it's a tyrosine kinase pathway, and the ligand that it attaches to is something called HGF/SF. That's hepatocyte growth factor/scatter factor. And so this MET pathway tyrosine kinase pathway is really important in tumor cell growth and migration. And it's expressed specifically on epithelial cells, so that's going to really help us in identifying how it can be a pathway for cancer treatments.” TS 1:35 “But in the particular classes, there kind of are some unique things that are with these MET inhibitors. For example, crizotinib, we found early on, causes some vision changes. Patients would report things like floaters or a little bit of blurry vision. For the capmatinib, things like elevation of amylase and lipase, fluid retention and bloating, and hypersensitivity reactions and photosensitivity.” TS 7:36 “Other things to teach for the TKI is the self-management strategies in terms of nausea management and dietary changes for the risk of peripheral edema. Having them do things like maybe doing daily weights, or at least weights every other day, and sometimes doing limb measurements so it can help us really quantify the amount of fluid retention they have. And then from a nursing perspective, meeting with these patients, is to do really good skin inspection. When people have peripheral edema, they're at risk for skin breakdown, and that can lead obviously to infection.” TS 16:06 “The biggest [misconception] is that people assume that all MET mutations are going to be equally responsive to the same targeted therapies, that all of the abnormalities are the same and react the same, and they really don't. We're really diving down and carving that pie thinner and thinner in terms of each individual MET abnormality, in terms of what drugs responds it to and what that means for patient outcomes and prognosis.” TS 25:21

On this week's episode, Dr. Cox struggles to support his best friend through Chemotherapy. In the real world, Zach and Donald are joined by Brendan Fraser! Brendan reveals his love of photography, that time he worked with Mos Def, and what it's like to be stopped by Scrubs fans nearly 20 years after his first appearance on the show. See omnystudio.com/listener for privacy information.